---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-015982"
form_type: "8-K"
ticker: "GKOS"
cik: "0001192448"
company_name: "GLAUKOS Corp"
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T12:16:29.273348+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Glaukos Q3 net loss $27.6M ($0.58 EPS); revenue down 4.6% YoY to $71.3M; raises 2022 sales outlook

## Summary
- Net sales $71.3M, down 4.6% reported (1.6% constant currency) vs $74.7M in Q3 2021.
- Net loss $27.6M ($0.58 diluted) vs net income $6.2M ($0.13) in prior year, which included $30M litigation settlement.
- Non-GAAP net loss $21.3M ($0.45) vs non-GAAP net loss $14.7M ($0.31) in Q3 2021.
- Updated 2022 net sales guidance to $278-280M from prior $275-280M; cash and investments $371M.
- Glaucoma net sales $53.7M, Corneal Health $17.5M; GAAP gross margin 76%, non-GAAP 84%.

## SEC filing metadata
- accession: 0001558370-22-015982
- form_type: 8-K
- ticker: GKOS
- cik: 0001192448
- company_name: GLAUKOS Corp
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1192448/000155837022015982/0001558370-22-015982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1192448/000155837022015982/gkos-20221102x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-015982
- JSON: https://secwatch.observer/filing/0001558370-22-015982.json
- Plain text: https://secwatch.observer/filing/0001558370-22-015982.txt

## Key facts
- Earnings Releases
  GLAUKOS Corp reported third quarter ended September 30, 2022 results: revenue $71.3 million, net income $27.6 million, EPS ($0.58) per diluted share. Guidance raised.
  - Period: third quarter ended September 30, 2022
  - Revenue: $71.3 million
  - Net income: $27.6 million
  - EPS: ($0.58) per diluted share
  - Guidance: raised
  - Result: reported results
  source text: of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2022. Key highlights include: ● Net sales of $71.3 million in Q3 2022. ● Glaucoma net sales of $53.7 million and Corneal Health net sales of $17.5 million in Q3 2022. ● Gross margin of approximately 76% and non-GAAP gross margin of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1192448/000155837022015982/0001558370-22-015982-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.